Cephalon
deliver more

www.cephalon.com

Cephalon, Inc.
41 Moores Road
P.O. Box 4011
Frazer, PA 19355
Phone 610-344-0200
Fax 610-344-0065

July 26, 2007

HAND-DELIVERED

Commissioner of Patents and Trademarks
Mail Stop: Hatch-Waxman PTE
Washington, D.C. 20231

Re: Application for Extension of Patent Term
Patent No. 4,927,855
Issued: May 22, 1990
Title: **Levorotatory Isomer of Benzhydrylsulfinyl Derivatives**
Inventor(s): Louis Lafon
Assignee: Laboratoire L. Lafon
Agent: Cephalon, Inc.
Attorney Docket No.: CP265

Sir:

Three (3) copies of the following documents are being forwarded herewith for appropriate action by the U.S. Patent and Trademark Office:

1. Application for Non-Interim Extension of Patent Term Based on Completed Regulatory Review of a New Drug Application as Provided Under 35 U.S.C. § 156;

2. Exhibits A through D;

3. A Fee Transmittal authorizing payment of $1,120.00 of the filing fee for this application; and

4. One (1) return postcard.

It is respectfully requested that the enclosed postcard be stamped with the date the enclosed documents are received by the PTO and that it be returned as soon as possible.

PTO/SB/17 (12-04v2)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Effective on 12/08/2004.
Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).

FEE TRANSMITTAL for FY 2005



	Complete if Known
Patent Number	4,927,855
Issued	May 22,1990
First Named Inventor	Louis Lafon
Attorney Docket No.	CP265

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit Card ☐ Money Order ☐ None ☐ Other (please identify) : _____

☒ Deposit Account Deposit Account Number: 03-1195 Deposit Account Name: Cephalon, Inc.

For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)

☒ Charge fee(s) indicated below ☐ Charge fee(s) indicated below, **except for the filing fee**

☒ Charge any additional fee(s) or underpayments of fee(s) Under 37 CFR 1.16 and 1.17 ☒ Credit any overpayments

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

FEE CALCULATION

1. BASIC FILING, SEARCH, AND EXAMINATION FEES

	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee ($)	Fee($)	Fee($)	Fee($)	Fee($)	Fee($)	Fees Paid ($)
Utility	300	150	500	250	200	100	____
Design	200	100	100	50	130	65	____
Plant	200	100	300	150	160	80	____
Reissue	300	150	500	250	600	300	____
Provisional	200	100	0	0	0	0	____

2. EXCESS CLAIM FEES

Fee Description	Fee ($)	Small Entity Fee ($)
Each claim over 20 (including Reissues)	50	25
Each independent claim over 3 (including Reissues)	200	100
Multiple dependent claims	360	180

Total Claims		Extra Claims	Fee($)		Fee Paid ($)
____	-20 or HP=	____	x ____	=	____

HP = highest number of total claims paid for, if greater than 20.

Indep. Claims		Extra Claims	Fee($)		Fee Paid ($)
____	- 3 or HP=	____	x ____	=	____

HP = highest number of independent claims paid for, if greater than 3.

Multiple Dependent Claims	
Fee ($)	Fee Paid ($)
____	____

3. APPLICATION SIZE FEE

If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is $250 ($125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).

Total Sheets		Extra Sheets		Number of each additional 50 or fraction thereof		Fee ($)	Fee Paid ($)
____	- 100 =	____	/ 50 =	____	(round **up** to a whole number) x		= ____

4. OTHER FEE(S)

	Fees Paid ($)
Non-English Specification, $130 fee (no small entity discount)	____
Other (e.g., late filing surcharge) : Application for Non –Interim Patent Term Extension Under 35 U.S.C. § 156	**$1,120.00**

SUBMITTED BY

Signature		Registration No. (Attorney/Agent) 45,185	Telephone 610.738.6356
Name (Print/Type)	Eric K. Voelk		Date July 26, 2007

The Commissioner is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 03-1195. A duplicate copy of this letter is enclosed.

Respectfully requested



Eric Voelk
Cephalon, Inc.
Registration No. 45,185

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	U.S. Patent 4,927,855
Issued:	May 22, 1990
Inventor:	Louis Lafon
Assignee:	Laboratoire L. Lafon
Agent:	Cephalon, Inc.
For:	**Levorotatory Isomer of Benzhydrylsulfinyl Derivatives**

Commissioner of Patents and Trademarks
Mail Stop: Hatch-Waxman PTE
Washington, D.C. 20231

APPLICATION FOR NON-INTERIM EXTENSION OF PATENT TERM BASED ON COMPLETED REGULATORY REVIEW OF A NEW DRUG APPLICATION AS PROVIDED UNDER 35 U.S.C. § 156

08/03/2007 EFLORES 00000020 031195 4927855
01 FC:1457 1120.00 DA

Sir:

Applicant Cephalon, Inc., ("Cephalon") owner and holder of a New Drug Application ("NDA") approval, hereby makes application under 35 U.S.C. § 156 for an extension of the term of U.S. patent 4,927,855 issued on May 22, 1990. The current expiration date of this patent is May 22, 2008, based on a one-year interim extension previously granted under 35 U.S.C. § 156(d)(5). The expiration date of the patent prior to the interim extension was May 22, 2007. The 60 day period following NDA approval expires on August 14, 2007. This application is being made prior to the expiration of such 60 day period.

Applicant respectfully requests a further extension of 700 days, or such greater or lesser period as to which Applicant is entitled in accordance with law. The requested extension of 700 days, when aggregated with the interim extension, provides that the '855 patent will be accorded a total period of extension of 1066 days under 35 U.S.C. § 156.

This application for extension is based on the approval of the new drug NUVIGIL™ (armodafinil) Tablets under the provisions of section 505(b) of the Food, Drug and Cosmetic Act. The sole active ingredient in NUVIGIL is armodafinil or 2-[(R)-(diphenylmethyl)sulfinyl]acetamide, a compound of the formula:



The active ingredient in NUVIGIL Tablets, methods of using the active ingredient, and the active ingredient in the form of a pharmaceutical composition for human drug use are claimed in the patent. Applicant believes that the NDA approval for NUVIGIL Tablets will be the first permitted commercial marketing or use of this active ingredient in the United States. The active ingredient in NUVIGIL is the isolated and purified levorotatory enantiomer of the active racemic ingredient in the previously approved drug product PROVIGIL®.

The assignee of the entire right, title and interest in U.S. patent 4,927,855 is Laboratoire L. Lafon by virtue of an assignment from the inventor Louis Lafon and such patent was issued by the U.S. Patent and Trademark office in the name of the aforementioned assignee. Laboratoire L. Lafon has changed its name to Cephalon France, as documented in **Exhibit A**. Applicant Cephalon, Inc. is the holder and owner of the aforementioned NDA for NUVIGIL Tablets and is making this application as the duly authorized agent of the assignee, for and in the name of the assignee. Attached as **Exhibit B** is a letter of appointment of agent from the assignee.

In accordance with the provisions of 37 C.F.R. § 1.740, Applicant provides the following information:

(1) A complete identification of the approved product as by appropriate chemical and generic name, physical structure or characteristics.

Applicant submits that the appropriate chemical and generic name for the active ingredient in NUVIGIL Tablets has been set forth above. Otherwise, armodafinil is an enantiomeric compound with a molecular weight is 273.35 and is typically prepared as a white to off-white, crystalline powder that is very slightly soluble in water, sparingly soluble in acetone and soluble in methanol.

(2) A complete identification of the Federal statute including the applicable provision of law under which the regulatory review occurred.

The approval for NUVIGIL Tablets by the Food and Drug Administration was pursuant to the regulatory review provisions of section 505(b) of the Food, Drug and Cosmetic Act, 21 U.S.C. § 355(b).

(3) An identification of the date on which the product received permission for commercial marketing or use under the provision of law under which the applicable regulatory period occurred.

June 15, 2007.

(4) An identification of each active ingredient in the product and a statement that each such active ingredient has not been previously approved for commercial marketing or use under the Federal Food Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act, or a statement of when the active ingredient was approved for commercial marketing or use (either alone or in combination with other active ingredients), the use for which it was approved, and the provision of law under which it was approved.

The active ingredient in NUVIGIL Tablets has not been previously approved for commercial marketing or use under the Federal Food Drug and Cosmetic Act, the Public Health Service Act, or the Virus-Serum-Toxin Act. The active ingredient in NUVIGIL is the isolated and purified levorotatory enantiomer of the active racemic ingredient in the drug product PROVIGIL, which has been previously approved for commercial marketing or use under the Federal Food Drug and Cosmetic Act.

(5) A statement that the application is being submitted within the sixty-day period permitted for submission pursuant to § 1.720(f) and an identification of the date of the last day on which the application could be submitted.

This application is being submitted within the 60 day period, the last day of which is believed by the Applicant to be August 14, 2007.

(6) A complete identification of the patent for which an extension is being sought by the name of the inventor, the patent number, the date of issue, and the date of expiration.

This application for extension relates to U.S. patent 4,927,855 issued on May 22, 1990 on a non-provisional application filed January 28, 1987 (claiming priority to a French patent application no. 86 01337 filed January 31, 1986), of Louis Lafon, which was set to expire on May 22, 2007, seventeen years from the U.S. patent issue date. This patent is assigned to Laboratoire L. Lafon (now known as Cephalon France), with respect to which the Applicant is its agent for the purpose of seeking extension. Attached as **Exhibit B** is a letter of appointment of agent from the assignee.

(7) A copy of the patent for which an extension is being sought, including the entire specification (including claims) and drawings.

A copy of the patent for which an extension is being sought, including the entire specification (including claims) appears in **Exhibit C.**

(8) A copy of any disclaimer, certificate of correction, receipt of maintenance fee payment, or reexamination certificate issued in the patent.

The patent for which extension is being sought has not been the subject of an disclaimer, certificate of correction, or reexamination certificate. Maintenance fee payments have been made on October, 25, 1993, November 24, 1997 and October 22, 2001, receipts of which are enclosed as **Exhibit D**.

(9) A statement that the patent claims the approved product or a method of using or manufacturing the approved product, and a showing which lists each applicable patent claim and demonstrates the manner in which each applicable patent claim reads on the approved product or a method of using or manufacturing the product.

The approved product is the active ingredient in NUVIGIL Tablets, armodafinil or 2-[(R)-(diphenylmethyl)sulfinyl]acetamide. The patent claims 1, 2 and 4-6 are directed to the approved product or a method of using the approved product or the approved product in the form of a pharmaceutical composition.

Patent Claim	*Relationship with Approved Product*
1. (-)-Benzhydrylsulfinylacetamide.	The active ingredient in proposed product is 2-[(R)-(diphenylmethyl)sulfinyl]acetamide, which has the same chemical name as (-)-Benzhydrylsulfinylacetamide.
2. A method for the treatment of hypersomnia, which comprises administering, to a patient in need of such a treatment, an effective amount of a pharmaceutical composition consisting essentially of (-)-benzhydrylsulfinylacetamide as an arousing agent.	The proposed indications for approval (excessive sleepiness with obstructive sleep apnea/hypopnea syndrome, narcolepsy, and shift work sleep disorder) are subclasses of hypersomnia.
4. A therapeutic composition comprising an amount (-)-benzhydrylsulfinylacetamide in combination with a physiologically acceptable excipient effective to serve as an arousing agent.	The proposed product, in the form of a therapeutic composition, is the subject of this claim. Refer to the characterization of claim 1 above.
5. A therapeutic composition comprising an amount effective as a central nervous system stimulant of (-)-benzhydrylsulfinylacetamide in combination with a physiologically acceptable excipient.	The proposed product, in the form of a therapeutic composition, is the subject of this claim. Refer to the characterization of claim 1 above.
6. A pharmaceutical composition useful in therapy as a central nervous system stimulant consisting essentially of (-)-benzhydrylsulfinylacetamide in combination with a physiologically acceptable medium.	The proposed product, in the form of a therapeutic composition, is the subject of this claim. Refer to the characterization of claim 1 above.

(10) **A statement beginning on an new page, of the relevant dates and information pursuant to 35 U.S.C. 156(g) in order to enable the Secretary of Health and Human Services or the Secretary of Agriculture, as appropriate, to determine the applicable regulatory review period, particularly, for a patent claiming a human drug, antibiotic, or human biological product, the effective date of the investigational new drug (IND) application and the IND number; the date on which a new drug application (NDA) or a Product License Application (PLA) was initially submitted and the NDA or PLA number and date on which the NDA was approved or the Product License issued.**

For the FDA approval of NUVIGIL Tablets the following are the applicable dates:

Effective date for IND	October 31, 2003
IND No.	68,517
Initial Submission of NDA	March 31, 2005
NDA No.	21-875
Approval for NDA	June 15, 2007

(11) A brief description beginning on a new page of the significant activities undertaken by the marketing applicant during the applicable regulatory review period with respect to the approved product and the significant dates applicable to such activities.

A brief description of significant activities undertaken by Cephalon, Inc. during the regulatory review period for NUVIGIL, together with applicable dates for such activities, are the following:

1. Between May 2003 and July 2006, Cephalon conducted at least 15 clinical studies.

2. The clinical development program included 6 studies of pharmacokinetics and pharmacodynamics, 5 multi-center randomized, double-blind, placebo-controlled parallel-group Phase 3 studies and 3 multicenter open-label, flexible-dosage Phase 3 studies.

3. Key regulatory and clinical study dates are as follows:

Key Regulatory Dates:

October 31, 2003	IND 68,517 submission to FDA
November 26, 2003	Clearance from FDA to proceed with clinical studies
October 22, 2004	Pre-NDA Meeting
March 31, 2005	NDA 21-875 submission
April 7, 2005	FDA acknowledged receipt of NDA
June 10, 2005	Provided FDA Reviewer's Aid
July 18, 2005	Response to FDA Request
August 19, 2005	Response to FDA Request
October 31, 2005	Response to FDA Request
January 30, 2006	FDA action date extension letter
February 10, 2006	Response to FDA Request
April 6, 2006	Response to FDA Request
June 30, 2006	Response to approvable letter
August 15, 2006	Type II DMF Original Submission for armodafinil
December 19, 2006	Response to FDA Request
December 22, 2006	FDA action date extension letter
February 23, 2007	Response to FDA Request
March 16, 2007	Response to FDA Request
April 16, 2007	Response to approvable letter
June 15, 2007	Approval from FDA

Key Clinical Study Dates:

May-June 2003	Study 101 (PK/tolerance)
June – Sept. 2003	Study 102 (PK/tolerance)
June – Sept. 2003	Study 103 (PK/PD)
May 2004	Study 1021 (extrinsic PK)

June – July 2004	Study 1022 (extrinsic PK)
July 2004	Study 1023 (bioequivalence)
Oct. – Dec. 2004	Study 1025 (extrinsic PK)
March 2004 – Jan 2005	Study 3020 (Phase 3: safety/efficacy)
Feb. – Nov. 2004	Study 3021 (Phase 3: safety/efficacy)
April – Dec. 2004	Study 3022 (Phase 3: safety/efficacy)
March – Oct. 2004	Study 3025 (Phase 3: safety/efficacy)
Feb. 2004 – July 2006	Study 3023 (Phase 3: safety/efficacy)
Feb. 2004 – July 2006	Study 3024 (Phase 3: safety/efficacy)
Sept. – Dec. 2005	Study 3045 (Phase 3: safety/efficacy)
Oct. 2004 – July 2006	Study 3046 (Phase 3: safety/efficacy)

4. Additional information related to the NDA was submitted by Cephalon to the FDA on the following dates:

June 7, 2005	January 12, 2006	January 22, 2007
June 10, 2005	January 25, 2006	February 7, 2007
June 13, 2005	January 27, 2006	February 13, 2007
June 24, 2005	February 10, 2006	February 14, 2007
August 12, 2005	March 24, 2006	February 23, 2007
August 19, 2005	April 5, 2006	February 27, 2007
September 27, 2005	April 6, 2006	March 16, 2007
September 29, 2005	June 30, 2006	March 20, 2007
October 28, 2005	August 11, 2006	March 29, 2007
October 31, 2005	November 13, 2006	April 16, 2007
December 16, 2005	December 19, 2006	

(12) A statement beginning on a new page that in the opinion of the applicant the patent is eligible for the extension and a statement as to the length of extension claimed, including how the length of extension was determined.

Applicant believes that based on the NDA approval date of June 15, 2007, U.S. patent 4,927,855 will be entitled to a further extension of 700 days in accordance with the provisions of 35 U.S.C. § 156. Applicant believes that the aggregate period of extension applicable to the patent is 1066 days, with 700 additional days following the grant of the interim extension. This calculation was made as follows:

	Patent Information:
Patent Issue Date	May 22, 1990
Non-Provisional U.S. Patent Priority Date	January 28, 1987
	FDA Information:
Date IND Becomes Effective	October 31, 2003
Date NDA Submitted to the FDA	March 31, 2005
Date NDA Approved by the FDA	June 15, 2007
	IND Period:
Start Date of Regulatory Review Period	October 31, 2003
IND Review Period (days)	518
½ IND Review Period (days)	259
	Reg. Rev. Period Allowed:
NDA Review Period (days)	***807***
Regulatory Review Period	1325
Reg. Review Period Less ½ IND Period (days)	1066
	Statutory Limitations:
Patent Expiration Date (>17 or 20 year term)	*May 22, 2007*
Expiration Under 5 Year Limitation Period	May 22, 2012
Expiration of 14 years from NDA Approval	June 15, 2021
Expiration Based on Regulatory Review Period	April 22, 2010
Maximum Extension Based on All Limitations:	***April 22, 2010***
Maximum Aggregate Extension in Days:	1066
Interim Extension Date:	May 22, 2008
Remaining Permitted Extension in days:	***700***

(13) A statement that applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services or the Secretary of Agriculture any information which is material to the determination of entitlement to the extension sought (see 37 C.F.R. § 1.765).

Applicant acknowledges a duty to disclose to the Commissioner of Patents and Trademarks and the Secretary of Health and Human Services or the Secretary of Agriculture any information which is material to the determination of entitlement to the extension sought.

(14) The prescribed fee for receiving and acting upon the application for extension (see 37 C.F.R. § 1.20(j)).

Applicant hereby encloses a Fee Transmittal authorizing payment of $1,120.00 of the filing fee for this application from Deposit Account No. 03-1195. If for any reason this payment is insufficient, Applicant hereby authorizes that any deficiency may be charged to Deposit Account No. 03-1195.

(15) The name, address and telephone number of the person to whom inquiries and correspondence relating to the application for patent term extension are to be directed:

Please direct all correspondence in connection with this application to:

Robert T. Hrubiec, Ph.D., J.D.
Vice President, Intellectual Property & Chief Patent Counsel
Cephalon, Inc.
41 Moores Road
PO Box 4011
Frazer, PA 19300

(16) A duplicate of the application papers, certified as such.

Applicant hereby certifies that this application is accompanied by 2 additional copies.

(17) An oath or declaration.

Applicant, through its undersigned patent attorney authorized to practice before the Patent and Trademark Office and who has general authority from the agent or owner to act on behalf of the agent or owner in patent matters, being duly warned that willful false statements are punishable by fine or imprisonment or both under section 1001 of Title 18, United States Code and that willful false statements and the like may jeopardize the validity of this application and the patent to which it relates, states and declares that the following statements made based on his

own knowledge are true and that all statements made on information and belief are believed to be true:

(1) The undersigned is registered to practice before the Patent and Trademark Office and is making this declaration as a patent attorney who has general authority to act on behalf of the Applicant in patent matters.

(2) The undersigned has reviewed and understands the contents of the application being submitted pursuant to this section;

(3) The undersigned believes the patent is subject to an extension pursuant to 37 C.F.R. § 1.710;

(4) The undersigned believes an extension of the length claimed is justified under 35 U.S.C. 156 and the applicable regulations; and

(5) The undersigned believes the patent for which extension is being sought meets the conditions for extension of the term of a patent as set forth in 37 C.F.R. § 1.720.

If this application for extension of patent term is held to be informal, Applicant may seek to have that holding reviewed by filing a petition with the required fee, as necessary, pursuant to 37 C.F.R. §§ 1.181, 1.182 or 1.183, as appropriate, within such time as may be set in any notice that the application has been held to be informal, or if no time is set, within one month of the date on which the application was held informal.

Respectfully submitted,

CEPHALON, INC.

Date: 7-26-07

By: _____

Eric Volk
Reg. No. 45,185
Director, Intellectual Property
Cephalon, Inc.

Attachments:
Fee Transmittal for $1,120.00
Exhibit A - Authorization for Changing Name of Laboratoire L. Lafon to Cephalon France
Exhibit B - Letter of appointment of agent
Exhibit C - Copy of U.S. patent 4,927,855
Exhibit D - Maintenance Fee Statements

EXHIBIT A

Authorization for Changing Name of Laboratoire L. Lafon to Cephalon France

LABORATOIRE L. LAFON
Société Anonyme au capital de € 11.553.920
Siège Social : 19, avenue du Professeur Cadiot 94700 Maisons-Alfort
552 061 962 RCS Créteil

PROCES-VERBAL DES DELIBERATIONS DE L'ASSEMBLEE GENERALE EXTRAORDINAIRE DU 12 FEVRIER 2003

L'an 2003,

Le mercredi 12 février,

A 14 heures,

Les actionnaires de la société LABORATOIRE L. LAFON, société anonyme au capital de € 11.553.920, divisé en 18.053 actions de € 640 chacune, dont le siège est 19, avenue du Professeur Cadiot, 94700 Maisons-Alfort, se sont réunis en Assemblée Générale Extraordinaire, au 20, rue Charles Martigny, 94700 Maisons-Alfort, sur convocation faite par le Conseil d'Administration selon lettre simple adressée à chaque actionnaire.

Il a été établi une feuille de présence, qui a été émargée par chaque membre de l'Assemblée en entrant en séance, tant en son nom qu'en qualité de mandataire.

L'Assemblée est présidée par Monsieur Alain Aragues, en sa qualité de Président du Conseil d'Administration.

Organisation de Synthèse Mondiale Orsymonde, représentée par Monsieur Alain Aragues, seul autre actionnaire présent et acceptant cette fonction, est appelée comme scrutateur unique.

Madame Ann Baugas est désignée comme secrétaire.

Monsieur Albert Rojtman, Commissaire aux Comptes titulaire, régulièrement convoqué par lettre recommandée avec demande d'avis de réception, est absent

Les membres du Comité d'Entreprise qui assistent à l'Assemblée sont :

Madame Elizabeth Jean

La feuille de présence, certifiée exacte par les membres du bureau, permet de constater que les actionnaires présents, représentés ou ayant voté par correspondance possèdent 18.050 actions sur les 18.053 actions ayant le droit de vote.

En conséquence, l'Assemblée, réunissant plus que le quorum requis par la loi, est régulièrement constituée et peut valablement délibérer.

Le Président dépose sur le bureau et met à la disposition des membres de l'Assemblée :

- les copies des lettres de convocation adressées aux actionnaires ;
- la copie et l'avis de réception de la lettre de convocation du Commissaire aux Comptes ;
- les copies des lettres de convocation adressées aux représentants du Comité d'Entreprise ;
- la feuille de présence et la liste des actionnaires ;
- un exemplaire des statuts de la Société ;
- le rapport du Conseil d'Administration ;
- le texte du projet des résolutions qui sont soumises à l'Assemblée.

Le Président déclare que les documents et renseignements prévus par les dispositions législatives et réglementaires ont été adressés aux actionnaires ou tenus à leur disposition au siège social pendant le délai fixé par lesdites dispositions.

L'Assemblée lui donne acte de cette déclaration.

Le Président rappelle que l'Assemblée est appelée à délibérer sur l'ordre du jour suivant :

ORDRE DU JOUR

- Lecture du rapport du Conseil d'Administration ;
- Modification de la dénomination sociale ;
- Transfert du siège social ;
- Modification corrélative des statuts ;
- Pouvoirs pour l'accomplissement des formalités.

Il est ensuite donné lecture du rapport du Conseil d'Administration.

Puis, le Président déclare la discussion ouverte.

Personne ne demandant la parole, le Président met successivement aux voix les résolutions suivantes :

PREMIERE RESOLUTION

L'Assemblée Générale, après avoir entendu la lecture du rapport du Conseil d'Administration, décide qu'à compter de ce jour, la dénomination sociale sera "CEPHALON FRANCE" au lieu de "LABORATOIRE L. LAFON".

Cette résolution est adoptée à l'unanimité.

DEUXIEME RESOLUTION

L'Assemblée Générale, après avoir entendu la lecture du rapport du Conseil d'Administration, décide de transférer le siège social du 19, avenue du Professeur Cadiot, 94700 Maisons-Alfort au 20, rue Charles Martigny, 94700 Maisons-Alfort, et ce à compter de ce jour.

Cette résolution est adoptée à l'unanimité.

TROISIEME RESOLUTION

En conséquence de l'adoption des résolutions précédentes, l'Assemblée Générale décide de modifier les articles 3 et 4 des statuts de la Société dont la rédaction est désormais la suivante :

ARTICLE 3 - Dénomination

"La dénomination de la Société est : CEPHALON FRANCE."

Le reste de l'article demeure inchangé.

ARTICLE 4 - Siège social

"Le siège social est fixé au : 20, rue Charles Martigny, 94700 Maisons-Alfort."

Le reste de l'article demeure inchangé.

Cette résolution est adoptée à l'unanimité.

QUATRIEME RESOLUTION

L'Assemblée Générale donne tous pouvoirs au porteur de copies ou d'extraits du présent procès-verbal pour remplir toutes formalités de droit.

Cette résolution est adoptée à l'unanimité.

L'ordre du jour étant épuisé et personne ne demandant plus la parole, le Président déclare la séance levée.

De tout ce que dessus, il a été dressé le présent procès-verbal qui, après lecture, a été signé par les membres du bureau.

Le Président

Le Scrutateur unique

Le Secrétaire

42622.1.10

Certifié Conforme

EXHIBIT B

Letter of appointment of agent

AUTHORIZATION AND POWER OF ATTORNEY

May 7, 2007

Cephalon, Inc.
Attention: Robert T. Hrubiec, Vice President, Intellectual Property and Chief Patent Counsel
41 Moores Road
Frazer, PA 19380

Re: U.S. Patent 4,927,855

Dear Dr. Hrubiec:

Laboratoire L. Lafon, a corporation organized under the laws of France and assignee of the entire right, title and interest in U.S. Patent 4,927,855, hereby appoints Cephalon, Inc. as its agent under 35 U.S.C. 156(d)(1) and 156(d)(5)(c) to seek patent term extensions, including interim extensions, of the aforementioned U.S. Patent 4,927,855 with full authority to apply for and to receive any such extension for and on behalf of Laboratoire L. Lafon.

Respectfully submitted,

LABORATOIRE L. LAFON

By: _____
Name: Robert P. Roche, Jr
Title: Director

EXHIBIT C

Copy of U.S. patent no. 4,927,855

EXHIBIT D

Maintenance Fee Statements

Return To:

USPTO Home Page

Finance Online Shopping Page

United States Patent and Trademark Office

Patent Bibliographic Data					07/25/2007 12:03 PM
Patent Number:	4927855		**Application Number:**	07007720	
Issue Date:	05/22/1990		**Filing Date:**	01/28/1987	
Title:	LEVOROTATORY ISOMER OF BENZHYDRYLSULFINYL DERIVATIVES				
Status:	4th, 8th and 12th year fees paid			**Entity:**	Large
Window Opens:	N/A	**Surcharge Date:**	N/A	**Expiration:**	N/A
Fee Amt Due:	Window not open	**Surchg Amt Due:**	Window not open	**Total Amt Due:**	Window not open
Fee Code:					
Surcharge Fee Code:					
Most recent events (up to 7):	10/22/2001 11/24/1997 12/28/1993 12/28/1993 11/05/1993 10/27/1993 10/25/1993	Payment of Maintenance Fee, 12th Year, Large Entity. Payment of Maintenance Fee, 8th Year, Large Entity. Payor Number Assigned. Payer Number De-assigned. Payor Number Assigned. Pat Hldr no Longer Claims Small Ent Stat as Small Business. Payment of Maintenance Fee, 4th Year, Large Entity. --- End of Maintenance History ---			
Address for fee purposes:	ACCUMAS COMPUTER PACKAGES INC. 414 HUNGERFORD DRIVE ROCKVILLE, MD 20850				

Run Another Query

Need Help? | USPTO Home Page | Finance Online Shopping Page

Return To:

USPTO Home Page

Finance Online Shopping Page

United States Patent and Trademark Office

Maintenance Fee Statement

07/25/2007 12:05 PM EDT

Patent Number: 4927855

Customer Number: 337

ACCUMAS
COMPUTER PACKAGES INC.
414 HUNGERFORD DRIVE
ROCKVILLE MD 20850

According to the records of the U.S.Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O.Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR-CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
4,927,855	$930.00	$0.00	10/25/93	07/007,720	05/22/90	01/28/87	04	NO	FL-1006-US

Click here to obtain your Maintenance Fee Statement as a PDF.
Please note that in order to view your Maintenance Fee Statement as a PDF, you must have Adobe's Acrobat Reader installed. If you do not have it, download it for FREE!

Get Acrobat Reader

Return To:

USPTO Home Page

Finance Online Shopping Page

United States Patent and Trademark Office

Maintenance Fee Statement

07/25/2007 12:05 PM EDT

Patent Number: 4927855

Customer Number: 337

ACCUMAS
COMPUTER PACKAGES INC.
414 HUNGERFORD DRIVE
ROCKVILLE MD 20850

According to the records of the U.S.Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O.Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR-CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
4,927,855	$2,100.00	$0.00	11/24/97	07/007,720	05/22/90	01/28/87	08	NO	FL-1006-US

Click here to obtain your Maintenance Fee Statement as a PDF.
Please note that in order to view your Maintenance Fee Statement as a PDF, you must have Adobe's Acrobat Reader installed. If you do not have it, download it for FREE!

Get Acrobat Reader

Return To:

USPTO Home Page

Finance Online Shopping Page

United States Patent and Trademark Office

Maintenance Fee Statement

07/25/2007 12:06 PM EDT

Patent Number: 4927855

Customer Number: 337

ACCUMAS
COMPUTER PACKAGES INC.
414 HUNGERFORD DRIVE
ROCKVILLE MD 20850

According to the records of the U.S.Patent and Trademark Office (USPTO), the maintenance fee and any necessary surcharge have been timely paid for the patent listed below. The "PYMT DATE" column indicates the payment date (i.e., the date the payment was filed).

The payment shown below is subject to actual collection. If the payment is refused or charged back by a financial institution, the payment will be void and the maintenance fee and any necessary surcharge unpaid.

Direct any questions about this statement to: Mail Stop M Correspondence, Director of the USPTO, P.O.Box 1450, Alexandria, VA 22313-1450.

PATENT NUMBER	FEE AMT	SUR-CHARGE	PYMT DATE	U.S. APPLICATION NUMBER	PATENT ISSUE DATE	APPL. FILING DATE	PAYMENT YEAR	SMALL ENTITY?	ATTY DKT NUMBER
4,927,855	$3,100.00	$0.00	10/22/01	07/007,720	05/22/90	01/28/87	12	NO	FL-1006-US

Click here to obtain your Maintenance Fee Statement as a PDF.
Please note that in order to view your Maintenance Fee Statement as a PDF, you must have Adobe's Acrobat Reader installed. If you do not have it, download it for FREE!

Get Acrobat Reader